151 related articles for article (PubMed ID: 4012338)
1. Pharmacologically directed ara-C therapy for refractory leukemia.
Plunkett W; Iacoboni S; Estey E; Danhauser L; Liliemark JO; Keating MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):20-30. PubMed ID: 4012338
[TBL] [Abstract][Full Text] [Related]
2. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
3. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
4. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
6. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
[TBL] [Abstract][Full Text] [Related]
7. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
8. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
Plunkett W; Keating M
Adv Exp Med Biol; 1986; 195 Pt B():171-5. PubMed ID: 3766228
[No Abstract] [Full Text] [Related]
9. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
10. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
Plunkett W; Liliemark JO; Estey E; Keating MJ
Semin Oncol; 1987 Jun; 14(2 Suppl 1):159-66. PubMed ID: 3589690
[No Abstract] [Full Text] [Related]
11. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
[TBL] [Abstract][Full Text] [Related]
12. Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells.
Riva-Lavieille C; Ressayre C; Barra Y; Carcassonne Y; Iliadis A
Ther Drug Monit; 1994 Aug; 16(4):375-9. PubMed ID: 7974627
[TBL] [Abstract][Full Text] [Related]
13. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Estey EH; Keating MJ; McCredie KB; Freireich EJ; Plunkett W
Leukemia; 1990 Feb; 4(2):95-9. PubMed ID: 2304361
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
Heinemann V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1989 May; 7(5):622-8. PubMed ID: 2709090
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
Yamauchi T; Kawai Y; Kishi S; Goto N; Urasaki Y; Imamura S; Fukushima T; Yoshida A; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Hug V; Keating MJ; Chubb S
Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologically directed design of leukemia therapy.
Plunkett W; Heinemann V; Estey E; Keating M
Haematol Blood Transfus; 1990; 33():610-3. PubMed ID: 2182451
[TBL] [Abstract][Full Text] [Related]
18. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
Liliemark JO; Gahrton G; Paul CY; Peterson CO
Semin Oncol; 1987 Jun; 14(2 Suppl 1):167-71. PubMed ID: 3589691
[TBL] [Abstract][Full Text] [Related]
19. Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.
Rustum YM; Slocum HK; Wang G; Bakshi D; Kelly E; Buscaglia D; Wrzosek C; Early AP; Preisler H
Med Pediatr Oncol; 1982; 10 Suppl 1():33-43. PubMed ID: 7162465
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]